CIK 0001728117 · Non-accelerated filer<br>Smaller reporting company
Gossamer Bio, Inc.
Sign in to watch- Ticker
- GOSS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 475461709
- Phone
- (858) 684-1300
- Business address
- 3115 MERRYFIELD ROW, SUITE 120, SAN DIEGO, CA, 92121
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 6 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2019-09-17 | Omega Fund V, L.P. 10% owner | Sale | −23,400 | $21.62 | $506K | 6,782,623 |
| 2019-09-16 | Omega Fund V, L.P. 10% owner | Sale | −13,213 | $21.52 | $284K | 6,806,023 |
| 2019-09-11 | Omega Fund V, L.P. 10% owner | Sale | −80,403 | $21.31 | $1.7M | 6,819,236 |
| 2019-09-10 | Omega Fund V, L.P. 10% owner | Sale | −32,373 | $21.00 | $680K | 6,899,639 |
| 2019-09-06 | Omega Fund V, L.P. 10% owner | Sale | −8,700 | $21.51 | $187K | 6,932,012 |
| 2019-09-05 | Omega Fund V, L.P. 10% owner | Sale | −12,704 | $21.60 | $274K | 6,940,712 |
| 2019-08-29 | Salter-Cid Luisa Chief Scientific Officer | Sale | −26,252 | $20.09 | $527K | 124,056 |
| 2019-08-28 | Salter-Cid Luisa Chief Scientific Officer | Sale | −23,748 | $19.65 | $467K | 150,308 |
| 2019-06-10 | Stampacchia Otello Director | Grant or award · Stock Option (right to buy) | +23,500 | 23,500 | ||
| 2019-06-10 | GALA RENEE D Director | Grant or award · Stock Option (right to buy) | +23,500 | 23,500 | ||
| 2019-06-10 | Daniel Thomas O Director | Grant or award · Stock Option (right to buy) | +23,500 | 23,500 | ||
| 2019-06-10 | Cox Russell J. Director | Grant or award · Stock Option (right to buy) | +23,500 | 23,500 | ||
| 2019-06-10 | Burow Kristina Director | Grant or award · Stock Option (right to buy) | +23,500 | 23,500 | ||
| 2019-06-10 | Bilenker Joshua H. Director | Grant or award · Stock Option (right to buy) | +23,500 | 23,500 | ||
| 2019-05-30 | Giraudo Bryan Chief Financial Officer | Purchase | +1,000 | $18.70 | $19K | 1,000 |
| 2019-03-25 | Dupont Jakob Chief Medical Officer | Grant or award · Stock Option (right to buy) | +65,000 | 65,000 | ||
| 2019-03-25 | Salter-Cid Luisa Chief Scientific Officer | Grant or award · Stock Option (right to buy) | +120,000 | 120,000 | ||
| 2019-03-25 | Christian Waage EVP & General Counsel | Grant or award · Stock Option (right to buy) | +105,000 | 105,000 | ||
| 2019-03-25 | Giraudo Bryan Chief Financial Officer | Grant or award · Stock Option (right to buy) | +145,000 | 145,000 | ||
| 2019-03-25 | Gujrathi Sheila President & CEO | Grant or award · Stock Option (right to buy) | +380,000 | 380,000 |
Page 19 of 21 · 401 trades